Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press84510.17650/1994-4098-2021-17-2-58-67MAMMOLOGY. REVIEWSМАММОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИRibociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practiceРибоциклиб в лечении больных HR+ HER2-отрицательным распространенным раком молочной железы: обновленные результаты рандомизированных клинических исследований и их роль для клинической практикиhttps://orcid.org/0000-0002-1124-6802KolyadinaI. V.КолядинаИ. В.
Russian Federation

2/1 Barrikadnaya St., Moscow 125993, Russia

4 Akademika Oparina St., Moscow 117997, Russia

Россия, 125993 Москва, ул. Баррикадная, 2/1, стр. 1

Россия, 117997 Москва, ул. Академика Опарина, 4

irinakolyadina@yandex.comRussian Medical Academy of Postgraduate Education, Ministry of Health of RussiaФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииV.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава России200920211721809202118092021https://ojrs.abvpress.ru/ojrs/article/view/845

The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life expectancy of patients. This review presents the features of the mechanism of action of CDK4/6 inhibitors, the most significant and updated results of large, randomized trials with ribociclib (MONALEESA-2, MONALEESA-3, and MONALEESA-7) assessing the efficacy and safety of combined endocrine therapy with various endocrine partners in a population of premenopausal women and menopausal patients. The prospects for the use of CDK4/6 inhibitors for therapy patients with visceral crisis are shown.

Люминальный HER2‑отрицательный подтип является доминирующим вариантом в структуре распространенного рака молочной железы. Современная комбинированная эндокринотерапия с ингибиторами CDK4/6 позволила существенно изменить прогноз заболевания за счет не только увеличения выживаемости до прогрессирования, но и существенной пролонгации продолжительности жизни больных. В настоящем обзоре представлены особенности механизма действия ингибиторов CDK4/6, наиболее значимые и обновленные результаты крупных рандомизированных исследований с рибоциклибом (MONALEESA‑2, MONALEESA‑3 и MONALEESA‑7) с оценкой эффективности и безопасности комбинированной эндокринотерапии с различными эндокринными партнерами в популяции пременопаузальных женщин и пациенток в менопаузе. Показаны перспективы применения ингибиторов CDK4/6 при развитии висцерального криза.

combined endocrine therapyinhibitors CDK4/6ribociclibMONALEESA-2MONALEESA-3MONALEESA-7visceral crisisкомбинированная эндокринотерапияингибиторы CDK4/6рибоциклибMONALEESA-2MONALEESA-3MONALEESA-7висцеральный кризCancer Today. Available at: https://gco.iarc.fr/today/online-analysis.Cardoso F., Paluch-Shimon S., Senkus E. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020;31(12):1623–49. DOI: 10.1016/j.annonc.2020.09.010.Zhukova L.G., Andreeva Yu.Yu., Zavalishina L.E. et al. Breast cancer. Sovremennaya onkologiya = Modern Oncology 2021;23(1):5–40. (In Russ.). DOI: 10.26442/18151434.2021.1.200823.Жукова Л.Г., Андреева Ю.Ю., Завалишина Л.Э. и др. Рак молочной железы. Современная онкология 2021;23(1):5–40.Serra F., Lapidari P., Quaquarini E. et al. Palbociclib in metastatic breast cancer: current evidence and real-life data. Drugs Context 2019;8:212579. DOI: 10.7573/dic.212579.Im S., Lu Y., Bardia A. et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019;381:307–16. DOI: 10.1056/NEJMoa1903765.Martin M., Garcia-Saenz J., Manso L. et al. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer. Future Oncol 2020;16(33):2763–78. DOI: 10.2217/fon-2020-0604.Schettini F., De Santo I., Rea C.G. et al. CDK4/6 inhibitors as single agent in advanced solid tumors. Front Oncol 2018;8:608.Rossi V., Berchialla P., Giannarelli D. et al. Should all patients with OP-positive HER2-negative metastatic breast cancer receive CDK4/6 inhibitor as first-line based therapy? A network meta-analysis of data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT trials. Cancers 2019;11:1661. DOI: 10.3390/cancers11111661.Klein M.E., Kovatcheva M., Davis L.E. et al. CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought. Cancer Cell 2018;34(1):9–20. DOI: 10.1016/j.ccell.2018.03.023.Delach S., Caponigro G. Preclinical headto- head comparison of CDK4/6 inhibitor activity toward CDK4 vs CDK6. Poster PS19-10. SABCS, 8–11 December, 2020.Bellet M., Faten A., Villanueva R. et al. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther Adv Med Oncol 2019;11:1758835919833867.Slamon D.J., Neven P., Chia S. et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 2020;382(6):514–24.Yardley D., Nusch A., Yap Y. et al. Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials. Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.1054.Spring L.M., Zangardi M., Moy B., Bardia A. Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations. The Oncologist 2017;22:1039–48.Cronin K., Berry D. Concern regarding age distribution of breast cancer. JAMA Surg 2018;153(11):1060, 1061. DOI: 10.1001/jamasurg.2018.2087.Fredholm H. Long-term outcome in young women with breast cancer: a population-based study. Breast Cancer Res Treat 2016;160(1):131–43.Tripathy D., Im S.A., Colleoni M. et al. Ribociclib plus endocrine therapy for premenopausal women with hormonereceptor- positive, advanced breast cancer (MONALEESA-7): a randomised Phase 3 trial. Lancet Oncol 2018;19(7):904–15.Hurvitz S.A., Franke F., Villanueva- Vazquez R. et al. Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2– advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: overall survival (OS) results. J Clin Oncol 2019;37(18 Suppl):LBA1008. DOI: 10.1177/1758835920943065.Bardia A. Tamoxifen or a nonsteroidal aromatase inhibitor with ribociclib in premenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 subgroup analysis. Poster 330P. Poster presented at: European Society for Medical Oncology Congress, October 19–23, 2018.Beck J.T. Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, -7 trials. Paper presented at: San Antonio Breast Cancer Symposium, December 4–8, 2018.Yardley D.A. Poster P139. ASCO 2020.Tripathy D. Poster PD2-04. SABCS 2020.Lu Y. Oral presentation. ESMO BC 2021.Cejalvo J.M., Martinez de Dueñas E., Galván P. et al. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. Cancer Res 2017;77(9):2213–21. DOI: 10.1158/0008-5472.CAN-16-2717.Johansson A., Trewin C., Hjerkind K. et al. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int J Cancer 2019;144(6):1251–61. DOI: 10.1002/ijc.31950.Sonke G., Hart L., Campone M. et al. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptorpositive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat 2018;167:659–69. DOI: 10.1007/s10549-017-4523-y.Hortobagyi G. Ribociclib for the first-line treatment of advanced hormone receptorpositive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Res 2018;20:123. DOI: 10.1186/s13058-018-1050-7.O’Shaughnessy J., Petrakova K., Sonke G. et al. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat 2018;168:127–34. DOI: 10.1007/s10549-017-4518-8.Im S.A., Mukai H., Park I.H. et al. Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study. J Glob Oncol 2019;5:1–19. DOI: 10.1200/JGO.18.00173.Johnston S., Martin M., Di Leo A. et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 2019;5:5. DOI: 10.1038/s41523-018-0097-z.Slamon D.J., Neven P., Chia S. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 2018;36(24):2465–72.Slamon D.J., Neven P., Chia S. et al. Overall survival (OS) results of the phase III MONALEESA 3 trial of postmenopausal patients (PTS) with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2–) advanced breast cancer (ABC) treated with fulvestrant (FUL) + ribociclib (RIB). Ann Oncol 2019;30(Suppl 5):v856–7.Slamon D.J., Neven P., Chia S. et al. Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2– advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). J Clin Oncol 2021;15(Suppl):1001. DOI: 10.1200/JCO.2021.39.15_suppl.1001. Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1001.Dawood S., Brzozowski K. Efficacy of CDK4/6i in the visceral crisis setting: Result from a real-world database. J Clin Oncol 2021;15(Suppl):1047. DOI: 10.1200/JCO.2021.39.15_suppl.1047. Available at: https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1047.